NIDA Bets $15.5 Million on a TAAR1 Drug for Cocaine Addiction

The National Institute on Drug Abuse has committed up to $15.5 million over five years to Newleos Therapeutics for mid-stage testing of an experimental addiction medication in cocaine use disorder, the Boston company said Tuesday. Separately, the Food and Drug Administration granted the same molecule, NTX-2001, a Fast Track designation for alcohol use disorder.

The grant is milestone-based and is the company's first federal award. Per Newleos' announcement, it carries NTX-2001 through a Phase 1 drug-drug interaction study and then a Phase 2 efficacy trial in cocaine use disorder, a diagnosis for which no medication has been approved in the United States.

Cocaine is the part of the addiction portfolio where the pharmacopeia is emptiest. Buprenorphine, methadone and naltrexone cover opioid use disorder; several drugs are approved for alcohol use disorder. For stimulants, the treatment system still runs almost entirely on behavioral care.

The gap the money is aimed at

Newleos puts the size of the cocaine use disorder population at more than 1.4 million adults and says overdose deaths involving cocaine rose more than sixfold between 2010 and 2023. Those figures come from the company's release rather than from a new federal report, and the mortality trend itself is not in dispute in the public health literature: cocaine deaths climbed through the period when fentanyl began appearing in the powder supply.

The company's argument for a drug is that the behavioral alternatives are thin. In its own words, contingency management and cognitive behavioral therapy are "only moderately effective and are limited by poor adherence." Contingency management, which pays patients for verified abstinence, has the stronger evidence base of the two but is not consistently available across treatment programs.

Federico Bolognani, Newleos' co-founder and chief medical officer, put the clinical case plainly in the release: "Cocaine use disorder is a serious, growing public health crisis with no FDA-approved pharmacotherapies available today, and this NIDA award provides funding to advance NTX-2001 through Phase 2 studies."

Both parts of that statement are doing work. The absence of approved stimulant medications is a fact of the current formulary. Whether NTX-2001 fills the gap is not, and the grant does not imply that it will — the money buys studies, not an answer.

Fast Track is a scheduling tool, not a verdict

The FDA designation for alcohol use disorder is easy to misread as a regulatory judgment about effectiveness. It is not. Fast Track gives a sponsor more frequent meetings and written correspondence with the agency during development, and makes a product eligible for accelerated approval or priority review later. It does not shorten the evidence requirement, and it does not mean the agency has reviewed efficacy data and found them persuasive.

For NTX-2001 the alcohol data are still being generated. Newleos is running a Phase 1b proof-of-concept study in the United States that compares the drug with placebo on alcohol consumption using the alcohol drinking paradigm, a translational model in which participants can drink in a controlled setting. The study also measures safety, tolerability and pharmacokinetics. Topline results are expected in the first half of 2027.

Alcohol use disorder, by the company's count, affects nearly 30 million people in the United States and is associated with more than 95,000 deaths a year. Three medications are already approved for it — naltrexone, acamprosate and disulfiram — and all three are underused, which is a separate problem from the one Newleos is trying to solve. A new mechanism would matter most for patients who have not responded to those options or who cannot take them.

The TAAR1 hypothesis

NTX-2001 is a selective partial agonist of trace amine-associated receptor 1, a G protein-coupled receptor expressed in brain regions that modulate dopamine signaling, including the reward and satiety circuitry. Newleos describes the mechanism as state-dependent: the drug is meant to damp excessive dopamine transmission and support insufficient transmission rather than simply blocking or flooding the system.

If that holds in humans, it would be unusual. Approved addiction medications work mostly by substituting for or blocking the target drug's receptor. A modulator that sits downstream of the receptor, on dopamine regulation itself, would in principle apply across drug classes — Newleos lists psychostimulants, opioids and alcohol as candidates — which is exactly the kind of claim that preclinical models are bad at settling.

The company says earlier trials of multiple formulations and dosing regimens found the drug safe and well tolerated. Those studies were not designed to show that it reduces drug use, and no peer-reviewed efficacy result in people has been published.

What to watch before 2027

Three things will decide whether this becomes a treatment story or a press release. The Phase 1b readout next year is the first: a placebo-controlled signal on drinking, with a safety and pharmacokinetics profile attached, is a real milestone; a well-tolerated drug with no effect on consumption is not.

The second is whether the Phase 2 cocaine trial actually enrolls and completes. Cocaine use disorder trials have historically struggled with recruitment and retention, and a milestone-based federal grant pays out only as steps are met, which means the headline number is a ceiling rather than a check.

The third is replication outside the company. TAAR1 has attracted sustained interest from psychiatric drug developers, and the receptor's biology is genuinely promising, but interest is not evidence. Until an independent group reproduces a behavioral effect in patients, the honest description of NTX-2001 is a plausible mechanism with a funded path and no efficacy data in people.

For patients and families, nothing changes this week. Medication-assisted treatment for opioid use disorder is available now and remains the standard of care where opioids are involved; for stimulant use there is still no approved drug, and the evidence-supported options are behavioral. People looking for help with alcohol use disorder or other substance use disorders can start with an assessment rather than waiting on a pipeline.